Swedish Orphan Biovitrum and Dongbao Group announce a distribution agreement for Iron Sucrose Rechon in Europe


                        
Stockholm,  Sweden  and  Shanghai,  China  -  November  3, 2010 - Swedish Orphan
Biovitrum  (STO: SOBI) and  Dongbao Group today  announced that Dongbao, through
its  subsidiary Rechon Life  Science Group (Rechon),  has granted Swedish Orphan
Biovitrum  (Sobi) the distribution rights to Iron Sucrose Rechon in geographical
Europe.

Under  the agreement, Sobi will pay to Rechon a regulatory approval milestone of
1,2 million  Euro. In addition, Sobi will pay  a transfer price and a royalty on
net sales to Rechon Life Science Ltd.

Iron  Sucrose  Rechon  is  an  intravenous  formulation of iron, used for anemia
treatment.  It is  in registrational  phase with  Sweden as rapporteur country.
Approval is expected by year end or early 2011, and a mutual recognition process
in Europe would be initiated immediately after an approval.

This  agreement is the first manifestation  of the strategic Commercial Alliance
that  the parties announced  in July, 2010.  In  the alliance, Sobi  will be the
marketing  and sales  partner of  choice for  Dongbao's pipeline  of products in
Europe,  and Dongbao will be the marketing and sales partner for selected Sobi's
products in China.

Dr.  Zhaoqi Li,  Vice President  of Dongbao  Enterprise Group  Co., Ltd. and the
Chairman  of Rechon  Life Science  Group expressed  that "We  are proud  to have
chosen  Sobi as partner to promote  and distribute Rechon's product Iron Sucrose
Rechon  to the  European market.  We are  also anxious  to start  the regulatory
process  for some  of Sobi's  interesting and  valuable products  in China. With
establishment  of mutual relationship between Sobi and Dongbao, we are confident
that our business goals will be achieved."

"Iron Sucrose Rechon is a good fit with Sobi's portfolio of hematology products.
This  is a first step  towards a very exciting  partnership, in which we will be
able  to provide  Dongbao's commercial  portfolio and  pipeline to patients with
medical  needs  in  Europe.  We  are  proud  and excited to work with Dongbao to
provide  our innovative and  valuable proprietary products  to patients who need
them in China," said Martin Nicklasson, CEO of Sobi.

About Iron Sucrose Rechon
Iron  Sucrose Rechon is a  form of iron sucrose.  Iron Sucrose is an intravenous
formulation  of iron, used  for the treatment  of Iron Deficiency.  The European
market  for intravenous iron is large and  growing. It is currently estimated at
over 100 million Euro in annual sales.

About Dongbao
Dongbao  is  a  conglomerate  industrial  group  with  more than 20 subsidiaries
operating  in China and several other countries.  As one of the leading supplier
of  biopharmaceutical products  in China,  Dongbao is  now working  closely with
partners  to  supply  first  class  pharmaceutical products worldwide. With well
established  marketing network  in China,  Dongbao is  also offering services to
introduce  and promote foreign pharmaceutical products to the Chinese market. No
matter  going out  or coming  into China,  Dongbao is offering mutual beneficial
solutions  to business partners.  The establishment of  partnership between Sobi
and  Dongbao  is  a  good  example  of such mutual beneficial partnership. Thus,
international   cooperation   is   playing   very  crucial  rules  in  Dongbao's
development.

For more information please contact:
Dr. Zhaoqi Li
Vice President of Dongbao Enterprise Group Co., Ltd. &
Chairman of the Board of Rechon Life Science Group
+86 21 63910001
E-mail:george@dongbao.com


About Rechon Life Science Group
Rechon  Life Science Ltd.  is a pharmaceutical  company developing and producing
high  value pharmaceutical products with  manufacturing operation in Sweden. The
company  can offer  customers the  entire process  of contract  manufacturing of
aseptic vials, ampoules and syringes as well as oral and nasal sprays from small
scale  batches for  clinical trials  up to  full-scale commercial production and
supply  to markets  worldwide including  the US,  Japan and  Europe. Rechon Life
Science  AB  is  now  providing  various  services  to  several  US and European
pharmaceutical,     biotech     and     life     science    companies.    Please
visitwww.rechon.com for more information.

For more information please contact:
Roland Holmqvist, Acting CEO
Rechon Life Science AB
Phone: +46 709 48 24 24
E-mail:roland.holmqvist@rechon.se


About Swedish Orphan Biovitrum
Swedish  Orphan  Biovitrum  is  a  Swedish  based niche specialty pharmaceutical
company  with  an  international  market  presence.  The  company  is focused on
providing  and developing  specialist pharmaceuticals  for rare disease patients
with  high medical needs.  The portfolio consists  of about 60 marketed products
and  an emerging late stage clinical development pipe-line. Our focus areas are:
hemophilia,  inflammation/autoimmune  diseases,  fat  malabsorption,  cancer and
inherited  metabolic disorders. Swedish Orphan  Biovitrum had pro-forma revenues
2009e of  about  2 BSEK  and  approximately  500 employees.  The  head office is
located  in Sweden and the share (STO:  SOBI) is listed on NASDAQ OMX Stockholm.
For more information please visitwww.sobi.com.

For more information please contact: Swedish Orphan Biovitrum AB (publ):
Erik Kinnman, VP Investor Relations
Phone:+46 73 422 15 40
E-mailerik.kinnman@sobi.com

Martin Nicklasson, CEO
Phone: +46 8 697 20 00


Swedish  Orphan Biovitrum may  be required to  disclose the information provided
herein  pursuant  to  the  Swedish  Securities  Markets Act. The information was
provided for public release on November 3, 2010 at 8:30 a.m. CET.




Subscribe

Documents & Links